Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Behnam Alirezaie"'
Publikováno v:
International Journal of Cancer Management. 15
Background: Oncolytic virotherapy can serve as a novel therapeutic strategy in oncology. In this study, we aimed to evaluate the oncolytic activity of the mumps virus RS-12 strain after its adaptation to cancer cells via serial passaging. Methods: To
Publikováno v:
Archives of Biotechnology and Biomedicine. 5:008-012
The sequence-independent, single-primer amplification (SISPA) enables the random amplification of nucleic acids, allowing the detection and genome sequencing of different viral agents. This feature of SISPA method provides evidence for application of
Autor:
Behnam Alirezaie, Ali Reza Khosravi, Ashraf Mohammadi, Roozbeh Fallahi, Arash Ghalyanchi Langeroudi
Publikováno v:
International Journal of Cancer Management. 13
Background: The use of oncolytic viruses as therapeutic agents is a promising treatment for various human cancers. Several viruses have been extensively examined to achieve tumor cell death. Objectives: This study aimed at evaluating the natural onco
Publikováno v:
Iranian Journal of Virology. 10:26-33
Publikováno v:
Acta virologica. 58:287-291
Attenuated mumps virus (MuV) RS-12 strain-based vaccine is one of several effective vaccines available in the prevention of mumps. Since previous studies have unveiled only about one-third of the attenuated vaccine RS-12 strain genome sequence, the r
Publikováno v:
Journal of Medical Virology. 83:897-903
The cell substrate has a pivotal role in live virus vaccines production. It is necessary to evaluate the effects of the cell substrate on the properties of the propagated viruses, especially in the case of viruses which are unstable genetically such
Publikováno v:
Iranian Journal of Virology. 3:35-38
Publikováno v:
Iranian Journal of Virology. 7:61-63
Publikováno v:
Journal of medical virology. 80(4)
RS-12 mumps virus strain was isolated in 1986, in monkey kidney cells, from the throat-washing of an Iranian patient and developed to RS-12 vaccine by serial passage of the pathogen in MRC-5 cells. During the present study, an early passage RS-12 con